Key result
Pentoxifylline use reduced the risks of ESRD and the composite renal outcome, but not mortality, in patients with predialysis stage 5 CKD.
Why the study?
Does pentoxifylline reduce the risk of ESRD and mortality in patients with predialysis stage 5 CKD?
Cohort (n=14,732)
Yes
Does pentoxifylline reduce the risk of ESRD and mortality in patients with predialysis stage 5 CKD?
Pentoxifylline may be efficacious in slowing progression to endstage renal disease in patients with advanced predialysis stage 5 chronic kidney disease.
Answers are grounded in this paper and cite their sources.
Pentoxifylline was associated with lower ESRD risk in stage 5 CKD; hypothesis-generating and requires RCT confirmation.
Few studies evaluated the effects of pentoxifylline on hard endpoints in patients with predialysis stage 5 chronic kidney disease (CKD). Thus, we tried to explore the effects of pentoxifylline and its interaction with renin-angiotensin-aldosterone system (RAAS) blockade on the development of endstage renal disease (ESRD) and mortality. This nationwide cohort study retrospectively included patients who had a serum creatinine level of >6 mg/dL and received erythropoiesis-stimulating agents (ESAs) between 2000 and 2010. We analyzed 7,366 pentoxifylline users and 7,366 propensity score-matched nonusers. Using Cox proportional hazard models, pentoxifylline reduced the risks of ESRD and the composite renal outcome but not that of mortality. In terms of the risks of developing ESRD, pentoxifylline alone exerted a comparable beneficial effect to combined therapy with an RAAS inhibitor and greater renoprotection than RAAS inhibitor monotherapy. This study suggests pentoxifylline is efficacious in slowing progression to ESRD in patients with predialysis stage 5 CKD.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2015) conducted a cohort in predialysis stage 5 chronic kidney disease (CKD) (n=14,732). Pentoxifylline vs. Propensity score-matched nonusers was evaluated on Development of endstage renal disease (ESRD) and mortality. Pentoxifylline use reduced the risks of ESRD and the composite renal outcome, but not mortality, in patients with predialysis stage 5 CKD.
Synapse has enriched 10 related papers. Consider them for comparative context: